Risk Assessment of Adrenal Insufficiency During Medication Withdrawal

Abstract

Adrenal insufficiency (AI) is a potentially life-threatening condition that can arise during or after withdrawal of medications, most notably glucocorticoids, but also other agents impacting the hypothalamic-pituitary-adrenal (HPA) axis. Early identification of at-risk patients is crucial to prevent morbidity and mortality associated with adrenal crises. This review synthesizes recent clinical evidence and guideline recommendations on the risk assessment of AI during medication withdrawal, focusing on epidemiology, pathophysiology, risk stratification, clinical presentation, diagnostic strategies, management, and emerging therapies, with an emphasis on practical implications for healthcare professionals.

Introduction

Withdrawal of medications that suppress the HPA axis, particularly glucocorticoids, is a common clinical scenario faced by physicians. Adrenal insufficiency during this period poses significant risks, including hemodynamic instability and adrenal crisis, especially in acutely ill patients. Understanding the mechanisms, identifying patients at risk, and following evidence-based protocols are paramount for safe medication tapering and withdrawal. This review aims to provide a comprehensive, up-to-date summary of the scientific and clinical aspects of AI risk assessment during medication withdrawal, grounded in recent PubMed-indexed literature and international guidelines.

Epidemiology / Disease Burden

The true incidence of AI during medication withdrawal is difficult to ascertain due to underdiagnosis and variable definitions. Studies estimate that up to 50% of patients on long-term systemic glucocorticoids may develop some degree of HPA axis suppression, with clinically significant AI occurring in 5-15% of cases during withdrawal. The risk is heightened in patients with prolonged high-dose exposure, but cases have also been reported after topical, inhaled, and intra-articular steroids. Morbidity is substantial, with AI contributing to hospitalizations, infections, and poor recovery from intercurrent illness, and mortality is increased in the context of adrenal crisis.

Pathophysiology

Medications that suppress the HPA axis, especially glucocorticoids, exert negative feedback at both hypothalamic and pituitary levels, reducing corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secretion. This leads to adrenal cortical atrophy and impaired endogenous cortisol synthesis. Upon withdrawal, the recovery of the HPA axis is variable and may take weeks to months. Other drugs, such as opioids, megestrol acetate, and immune checkpoint inhibitors, can also disrupt HPA function through central or direct adrenal mechanisms. The risk of AI is determined by the degree and duration of suppression, as well as individual patient factors influencing adrenal reserve.

Risk Factors

Major risk factors for AI during medication withdrawal include high-dose and prolonged duration of glucocorticoid therapy (e.g., >20 mg prednisone equivalent daily for >3 weeks), evening dosing, repeated courses, and use of long-acting formulations. Additional risk arises from concomitant medications affecting steroid metabolism (e.g., CYP3A4 inducers/inhibitors), underlying pituitary or hypothalamic disease, and preexisting adrenal pathology. Pediatric and elderly populations, those with rapid tapering, and patients with critical illness or sepsis are particularly vulnerable. Risk stratification tools and clinical decision algorithms have been proposed to aid in identifying high-risk individuals.

Clinical Features

AI during medication withdrawal can present insidiously or acutely. Symptoms often include fatigue, anorexia, weight loss, nausea, vomiting, abdominal pain, myalgia, arthralgia, and psychiatric manifestations such as depression or apathy. In severe cases, hypotension, hypoglycemia, hyponatremia, and hyperkalemia may occur, potentially escalating to adrenal crisis, especially under physiological stress (e.g., infection, surgery). Clinical suspicion must remain high, particularly in patients with recent steroid withdrawal presenting with nonspecific symptoms.

Diagnosis

Diagnosis of AI in the context of medication withdrawal is challenging due to nonspecific symptoms and variable laboratory findings. Basal morning serum cortisol <100 nmol/L (<3.6 μg/dL) suggests AI, while values >500 nmol/L (>18 μg/dL) generally exclude it. Intermediate values require dynamic testing, most commonly the standard (250 μg) or low-dose (1 μg) ACTH stimulation test. The insulin tolerance test is considered gold standard but is rarely used due to safety concerns. Interpretation may be confounded by concurrent illness, binding protein alterations, and assay variability. Clinical context, history of medication exposure, and time since withdrawal must be integrated into diagnostic decision-making.

Treatment & Management

Management of AI centers on glucocorticoid replacement using hydrocortisone or equivalent, tailored to physiological needs and adjusted for stress. During withdrawal, gradual tapering of exogenous steroids is recommended, allowing recovery of endogenous HPA function. Symptomatic patients or those with confirmed AI require maintenance therapy and education on stress dosing. Emergency parenteral hydrocortisone should be available for patients at risk of adrenal crisis. Electrolyte and hemodynamic monitoring, patient counseling, and clear documentation are essential components of care. Multidisciplinary collaboration enhances outcomes, particularly in hospitalized or complex patients.

Recent Advances / Emerging Therapies

Recent research has focused on refining risk stratification and diagnostic modalities for AI. Novel biomarkers (e.g., salivary cortisol, serum dehydroepiandrosterone sulfate) and improved ACTH stimulation protocols are under investigation. Personalized tapering regimens, informed by pharmacogenomics, may optimize recovery and reduce risk. In patients receiving immune checkpoint inhibitors, awareness of immune-related adrenalitis has increased, prompting monitoring protocols. Patient education tools, digital alerts in electronic health records, and interdisciplinary pathways are emerging to bridge gaps in recognition and prevention of AI during medication withdrawal.

Guideline Recommendations

Leading guidelines, including those from the Endocrine Society and European Society of Endocrinology, advocate for individualized risk assessment before, during, and after withdrawal of HPA-suppressive medications. Tapering strategies should be based on dose, duration, and patient-specific factors. Routine dynamic testing is recommended for patients at risk, especially if symptoms develop. Stress dosing education, medical alert identification, and clear communication across healthcare settings are strongly endorsed. Guidelines emphasize the need for heightened vigilance in high-risk cohorts and structured follow-up to ensure safe recovery of adrenal function.

Conclusion

Adrenal insufficiency during medication withdrawal remains a significant clinical challenge with potentially severe consequences. Risk assessment must be systematic, incorporating epidemiological, pathophysiological, and clinical insights. Early identification, appropriate diagnostic strategies, and evidence-based management are critical for reducing morbidity and mortality. Recent advances in risk stratification and patient-centered care offer promise but require integration into routine clinical practice. Ongoing education, multidisciplinary collaboration, and adherence to guideline recommendations are essential in safeguarding patients during and after withdrawal of HPA axis-suppressive medications.